TY - JOUR T1 - First Series of Patients With XDR and Pre-XDR TB Treated With Regimens That Included Meropenen-clavulanate in Argentina JO - Archivos de Bronconeumología T2 - AU - Palmero,Domingo AU - González Montaner,Pablo AU - Cufré,Mónica AU - García,Ana AU - Vescovo,Marisa AU - Poggi,Susana SN - 15792129 M3 - 10.1016/j.arbr.2015.07.003 DO - 10.1016/j.arbr.2015.07.003 UR - https://archbronconeumol.org/en-first-series-patients-with-xdr-articulo-S1579212915002773 AB - XDR (extensively drug-resistant) and pre-XDR tuberculosis (TB) seriously compromise prognosis and treatment possibilities, and inevitably require the use of group V drugs (World Health Organization). The progress of all patients with XDR and pre-XDR TB seen in a specialized unit during 2012 and 2013 and treated with regimens that included at least 6 months of meropenem-clavulanate (MPC), capreomycin, moxifloxacin, linezolid, clofazimine, high-dose isoniazid, PAS, and bedaquiline in 1 case, were retrospectively analyzed. Ten patients were treated, 9 with an extensive pattern of resistance to at least 6 drugs, and 1 because of adverse reactions and drug interactions leading to a similar situation. Eight of the 10 patients treated achieved bacteriological sputum conversion (2 consecutive negative monthly cultures) over a period of 2–7 months, while 2 died. No adverse reactions attributable to prolonged administration of MPC were observed. ER -